Compare Organon & Co. Common Stock (OGN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Xcel Energy Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Xcel Energy Inc trades at $75.4 (market cap $46.62B). The key difference: Xcel Energy Inc is far larger — about 12.9× Organon & Co. Common Stock's market cap, and Xcel Energy Inc pays the higher dividend (3.18%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Xcel Energy Inc for 61 Days on average.
| OGN | XEL | |
|---|---|---|
Market Cap | $3.62B | $46.62B |
Volume | 2,892,999 | 4,168,668 |
Sector | Health | Utilities |
52-Week High | $13.81 | $83.91 |
52-Week Low | $5.70 | $69.39 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $11.04B | $84.94B |
Dividend Yield | 0.58% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Xcel Energy (XEL) trades at $75.36, up 1.6% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results with a Q2 2026 beat (EPS $0.93 vs. $0.79 expected) but a Q4 2025 miss. Revenue for 2025 was $14.67B with a net income margin of 15.28%, while the company maintains a P/E of 20.45 and ROE of 9.92%. News highlights include partnerships for electric school buses and growth from data center power demand.
The outlook is positive, supported by a $60 billion capital expenditure plan and rising power demand, offering potential upside to the $90.58 consensus price target. Key risks include wildfire liabilities, high debt levels, and regulatory scrutiny. The stock presents a balanced opportunity for income and growth investors, with a dividend yield around 3.3% and institutional accumulation noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
